Esperamicin-A1Alternative Names: BBM 1675; BBM 1675A1; BMY 28175
Latest Information Update: 18 Feb 1997
At a glance
- Originator Bristol-Myers Squibb
- Class Aminoglycosides; Cytostatic antibiotics; Enediynes; Small molecules
- Mechanism of Action DNA inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 18 Feb 1997 Discontinued-Preclinical for Cancer in Japan (IV)